Market cap $51 M --Cash $52 M --3x Phase 3 readouts (potential Blockbuster) are imminent (during this quarter) ..Completely undiscovered ultra low float gem with significant upside potential Iterum (ITRM) Marktkap $51 M Cash: $52 M Price: $3.53 Shares Out 14.4 M “The second quarter was marked by continued progress in our three pivotal Phase 3 clinical trials of sulopenem,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics plc. “Based on current enrollment rates, we anticipate topline data from the complicated intra-abdominal (cIAI) and the complicated urinary tract infection (cUTI) trials in the fourth quarter. This would allow us the flexibility to file our new drug applications (NDAs) in the first quarter of 2020." take a look what insiders paid for their shares http://openinsider.com/search?q=itrm New Presentation https://d1io3yog0oux5.cloudfront.ne...2669/pdf/Iterum+Company+Deck_October+2019.pdf major shareholders: Canaan Partners ...1.7M Sofinnova ...1.7M Frazier ...1.5M New Leaf Venture ...1.5M Arix Bioscience ...1.1M Pivotal ...945.1K Malik (Shahzad) ...868.2K Advent Venture ...868.2K Cormorant Asset ...396.4K Franklin ...351.6K